The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Oct. 28, 2014

Filed:

Jun. 30, 2010
Applicants:

Alessio Moriconi, L'Aquila, IT;

Marcello Allegretti, L'Aquila, IT;

Maria Candida Cesta, L'Aquila, IT;

Riccardo Bertini, L'Aquila, IT;

Cinzia Bizzarri, L'Aquila, IT;

Francesco Colotta, L'Aquila, IT;

Inventors:

Alessio Moriconi, L'Aquila, IT;

Marcello Allegretti, L'Aquila, IT;

Maria Candida Cesta, L'Aquila, IT;

Riccardo Bertini, L'Aquila, IT;

Cinzia Bizzarri, L'Aquila, IT;

Francesco Colotta, L'Aquila, IT;

Assignee:

Dompe'S.p.A., L'Aquila, IT;

Attorney:
Primary Examiner:
Int. Cl.
CPC ...
A61K 31/192 (2006.01); A61K 31/40 (2006.01); A61K 31/405 (2006.01); A61K 31/407 (2006.01); C07D 209/26 (2006.01); C07C 311/09 (2006.01); C07C 57/58 (2006.01); C07D 209/42 (2006.01); C07C 311/21 (2006.01); C07D 471/04 (2006.01); C07D 295/13 (2006.01); C07D 207/337 (2006.01); C07C 57/30 (2006.01); C07C 311/51 (2006.01);
U.S. Cl.
CPC ...
C07D 207/337 (2013.01); C07D 209/26 (2013.01); C07C 311/09 (2013.01); C07C 57/58 (2013.01); C07D 209/42 (2013.01); C07C 311/21 (2013.01); C07D 471/04 (2013.01); C07D 295/13 (2013.01); C07C 57/30 (2013.01); C07C 311/51 (2013.01);
Abstract

Selected 2-arylacetic acids, their derivatives and pharmaceutical compositions that contain these compounds are useful in inhibiting chemotactic activation of neutrophils (PMN leukocytes) induced by the interaction of Interleukin-8 (IL-8) with CXCR1 and CXCR2 membrane receptors. The compounds are used for the prevention and treatment of pathologies deriving from their activation. In particular, 2(ortho)-substituted arylacetic acids or their derivatives, such as amides and sulfonamides, lack cyclo-oxygenase inhibition activity and are particularly useful in the treatment of neutrophil-dependent pathologies such as psoriasis, ulcerative colitis, melanoma, chronic obstructive pulmonary disease (COPD), bullous pemphigoid, rheumatoid arthritis, idiopathic fibrosis, glomerulonephritis and in the prevention and treatment of damages caused by ischemia and reperfusion.


Find Patent Forward Citations

Loading…